FindTrial
Sign In

Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19

Randomized Trial of ACEIs in Treatment of COVID-19

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04345406
Enrollment
60
Registered
2020-04-14
Start date
2020-04-15
Completion date
2029-12-01
Last updated
2020-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID

Brief summary

ACEIs as treatment for COVID19

Detailed description

ACEIs as suggested treatment for COVID19

Interventions

DRUGACEIs

Captopril or enalapril

DRUGConventional treatment

alexoquine

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients infected with covid 19

Exclusion criteria

* allergy or contraindications to the drug

Design outcomes

Primary

MeasureTime frameDescription
number of patients with virological cure6 monthsnumber of patients with virological cure

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam
sheriefabdelsalam@yahoo.com+201147773440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026